{"id":"NCT00931528","sponsor":"Radiation Therapy Oncology Group","briefTitle":"Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2012-12","completion":"2014-11","firstPosted":"2009-07-02","resultsPosted":"2016-07-27","lastUpdate":"2018-02-14"},"enrollment":242,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Prostate Cancer","Sexual Dysfunction"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tadalafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction.\n\nPURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.","primaryOutcome":{"measure":"Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)","timeFrame":"Baseline and 30 weeks from the start of radiation therapy","effectByArm":[{"arm":"Tadalafil","deltaMin":79,"sd":null},{"arm":"Placebo","deltaMin":74,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.49"},{"comp":"OG000 vs OG001","p":"0.2386"},{"comp":"OG000 vs OG001","p":"0.7908"},{"comp":"OG000 vs OG001","p":"0.0467"},{"comp":"OG000 vs OG001","p":"0.0068"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":192,"countries":["United States","Canada"]},"refs":{"pmids":["24691606"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":111},"commonTop":["Urinary frequency","Erectile dysfunction","Fatigue","Urinary urgency","Renal and urinary disorders - Other"]}}